Retinoic acid syndrome: Manifestations, pathogenesis, and treatment

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 3, 2003, Pages 453-461

  Larson, Richard S ^a   Tallman, Martin S ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute promyelocytic leukaemia; Retinoic acid syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; RETINOIC ACID;

ACUTE KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEVER; HUMAN; HYPOTENSION; LUNG INFILTRATE; MOLECULAR DYNAMICS; PATHOGENESIS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RESPIRATORY DISTRESS; RETINOIC ACID SYNDROME; REVIEW; WEIGHT GAIN; CELL ADHESION; ENDOTHELIUM CELL; EXTRAVASATION; FIBROSING ALVEOLITIS; LEUKEMIA CELL; LEUKOCYTE; PATHOPHYSIOLOGY;

EID: 0042830246     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00043-4     Document Type: Review

References (46)

1. Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine 1997; 337: 1021-1028.
2. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
3. Sanz MA, Lo CF Martin G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
4. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015-3021.
5. Lengfelder E, Reichert A, Schoch C et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362-1370.
6. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 110: 4298-4302.
7. Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90-95.
8. Vahdat L, Maslak P, Miller Jr. WH et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD 13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
9. De Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998; 92: 2712-2718.
10. Asou N, Adachi K, Tamura J et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. Journal of Clinical Oncology 1998; 16: 78-85.
11. Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukaemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
12. Shirono K, Kiyofuji C & Tsuda H. Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid. International Journal of Hematology 1995; 62: 183-187.
13. Ueno R, Takeuchi J, Shimizu T et al. [Development of Sweet's syndrome during all-trans retinoic acid therapy for acute promyelocytic leukemia.] Rinsho Ketsueki 2000; 41: 718-722.
14. Astudillo L, Loche F, Reynish W et al. Sweet's syndrome associated with retinoic acid syndrome in a patient with promyelocytic leukemia. Annals of Hematology 2002; 81: 111-114.
15. Giasuddin AS, El Orfi AH, Ziu MM & El Barnawi NY Sweet's syndrome: is the pathogenesis mediated by helper T cell type I cytokines? Journal of the American Academy of Dermatology 1998; 39: 940-943.
16. Nicolls MR, Terada LS, Tuder RM et al. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. American Journal of Respiratory and Critical Care Medicine 1998; 158: 1302-1305.
17. Raanani P, Segal E, Levi I et al. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA-a manifestation of the basic disease or the treatment. Leukemia & Lymphoma 2000; 37: 605-610.
18. Grignani F, Fagioli M, Alcalay M et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
19. Frankel SR, Eardley A, Lauwers G et al. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Annals of Internal Medicine 1992; 117: 292-296.
20. Degos L, Dombret H, Chomienne C et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-2653.
21. Salomon DS, Liotta LA, Rennard SI et al. Stimulation of retinoic acid of synthesis and turnover of basement membrane in mouse embryonal carcinoma-derived endoderm cells. Collager Related Research 1982; 2: 93-110.
22. Baggiolini M, Dewald B & Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Advances in Immunology 1994; 55: 97-179.
23. Masure S, Proost P, Van Damme J & Opdenakker G. Purification and identification of 91 -kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. European Journal of Biochemistry 1991; 198: 391-398.
24. Gianni M, Norio P, Terao M et al. Effects of dexamethasone on pro-inflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukaemia cells. European Cytokine Network 1995; 6: 157-165.
25. Hsu HC, Tsai WH, Chen PG et al. In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukaemic cells. European Journal of Haematology 1999; 63: 11-18.
26. Castaigne S, Chomienne C, Daniel MT et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-1709.
27. Fenaux P, Castaigne S, Chomienne C et al. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6 (supplement 1): 64-66.
28. McKee Jr. LC & Collins RD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimore) 1974; 53: 463-478.
29. Brown DC, Tsuji H & Larson RS. All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukaemia cell line NB-4 under physiologic flow. British Journal of Haematology 1999; 107: 86-98.
30. Marchetti M, Falanga A, Giovanelli S et al. All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. British Journal of Haematology 1996; 93: 360-366.
31. Thomas JG, Olson JM, Tapscott SJ & Zhao LP. An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles. Genome Research 2001; 11: 1227-1236.
32. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
33. Patel KD & McEver RP. Comparison of tethering and rolling of eosinophils and neutrophils through selectins and P-selectin glycoprotein ligand-I. Journal of Immunology 1997; 159: 4555-4565.
34. McEver RP. Leukocyte interactions mediated by selectins. Thrombosis and Haemostasis 1991; 66: 80-87.
35. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
36. Picker LJ & Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annual Review of Immunology 1992; 10: 561-591.
37. Omann GM, Allen RA, Bokoch GM et al. Signal transduction and cytoskeletal activation in the neutrophil. Physiology Reviews 1987; 67: 285-322.
38. Granger DN & Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. Journal of Leukocyte Biology 1994; 55: 662-675.
39. Luscinskas FW, Brock AF, Arnaout MA & Gimbrone Jr. MA. Endothelial-leukocyte adhesion molecule-I-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. Journal of Immunology 1989; 142: 2257-2263.
40. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-1036.
41. Albelda SM, Smith CW & Ward PA. Adhesion molecules and inflammatory injury. FASEB Journal 1994; 8: 504-512.
42. Bargatze RF, Jutila MA & Butcher EC. Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity 1995; 3: 99-108.
43. Larson RS, Brown DC & Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA- 1 and ICAM-2. Blood 1997; 90: 2747-2756.
44. Luscinskas FW, Ding H, Tan P et al. L- and P-selectins, but not CD49d (VLA-4) integrins, mediate monocyte initial attachment to TNF-alpha-activated vascular endothelium under flow in vitro. Journal of Immunology 1996; 157: 326-335.
45. Shibakura M, Niiya K, Kiguchi T et al. Simultaneous induction of matrix metalloproteinase-9 and interleukin 8 by all-trans retinoic acid in human PL-21 and NB4 myeloid leukaemia cells. British Journal of Haematology 2002; 118: 419-425.
46. Firkin F, Matthews J, Bradstock K et al. A phase II study of all-trans retinoic acid (ATRA) with prednisone prophylaxis in the treatment of acute promyelocytic leukemia (APL). Blood 1999; 94: 228b.